Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Otenabant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 20/20 | 0.98 |
| ▸ | CNR2 | P34972 | 15/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Otenabant SCHEMBL1622757 | 0.99 | CNR1 (1.00) | CNR1CNR2KCNH2 | |
| SCHEMBL5235768 | 0.93 | CNR1 (0.88) | CNR1CNR2 | |
| SCHEMBL1315332 | 0.92 | CNR1 (0.86) | CNR1CNR2KCNH2 | |
| SCHEMBL8012474 | 0.91 | CNR1 (0.85) | CNR1CNR2KCNH2 | |
| SCHEMBL5233761 | 0.91 | CNR1 (0.85) | CNR1CNR2KCNH2 | |
| SCHEMBL5240651 | 0.91 | CNR1 (0.84) | CNR1CNR2KCNH2 | |
| SCHEMBL30944012 | 0.90 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL30944092 | 0.88 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL5239445 | 0.88 | CNR1 (0.80) | CNR1CNR2KCNH2 | |
| SCHEMBL5238605 | 0.88 | CNR1 (0.79) | CNR1CNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4729940-A2 | LARGE SCALE ORGANOID ANALYSIS | Tempus AI, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260011445-A1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4070098-B1 | LARGE SCALE ORGANOID ANALYSIS | TEMPUS AI INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12451250-B2 | Systems and methods for predicting therapeutic sensitivity | TEMPUS AI, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20220341914-A1 | LARGE SCALE ORGANOID ANALYSIS | TEMPUS AI, INC. (F/K/A TEMPUS LABS, INC.) | 2022-10-27 | — | — | US | disclosed |
| US-11415571-B2 | Large scale organoid analysis | TEMPUS LABS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-20220175714-A1 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | SOOCHOW UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20200325543-A1 | DIAGNOSTIC METHOD | TOLREMO THERAPEUTICS AG (CH) | 2020-10-15 | — | — | US | disclosed |
| WO-2009004380-A1 | METHOD AND USE OF CIRCULATING LEVELS OF ENDOCANNABINOID LIGANDS FOR THE DETERMINATION OF PATIENT IN NEED AND/OR SUITABLE FOR CB1R ANTAGONIST DRUG TREATMENT AS WELL AS METHOD FOR INDUCING WEIGHT LOSS/MAINTENANCE/GAIN | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
| EP-1890767-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | Pfizer Products Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006129193-A2 | COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060270655-A1 | Combination therapy for treating obesity or maintaining weight loss | SWICK ANDREW G | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260011445-A1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | BRCA1, PARP2, PARP4 | CNR1 4143/4885CNR2 3611/4885KCNH2 4789/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | CNR1 3341/4885CNR2 3901/4885KCNH2 4572/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | CNR1 331/4885CNR2 634/4885KCNH2 3983/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | CNR1 2843/4885CNR2 724/4885KCNH2 1639/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | CNR1 1893/4885CNR2 2396/4885KCNH2 4045/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | CNR1 3341/4885CNR2 3901/4885KCNH2 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.